Cite
HARVARD Citation
Chung, H. et al. (2019). Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. Journal for immunotherapy of cancer. 7 (1), p. . [Online].